Genome Editing Market Forecasts to 2028 – Global Analysis By Product & Service (Reagents & Consumables, Services, Software & Systems, Cell Lines and Other Product & Services), By Technology (Clustered Regularly Interspaced Short Palindromic Repeats (CRISP

Genome Editing Market Forecasts to 2028 – Global Analysis By Product & Service (Reagents & Consumables, Services, Software & Systems, Cell Lines and Other Product & Services), By Technology (Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR), Zinc Finger Nuclease (ZFN), Transcription Activator-Like Effector Nuclease (TALEN), Antisense, Restriction Enzymes and Other Technologies), By Application (Cell Line Editing, Genetic Engineering, Drug Discovery & Development, Diagnostic Applications, Microorganisms Genetic Engineering, Gene Therapy and Other Applications), By End User (Clinical Research Organizations, Academics & Government Research Institutes, Pharmaceutical & Biotechnology Companies, Contract Research Organization and Other End Users) and By Geography


According to Stratistics MRC, the Global Genome Editing Market is accounted for $6.1 billion in 2022 and is expected to reach $18.5 billion by 2028 growing at a CAGR of 20.2% during the forecast period. Gene editing is the use of instruments and processes that significantly change the genetic blueprints of a living thing by making extremely particular alterations to the DNA sequence of a gene. Gene editing strives to modify particular target regions, as opposed to genetic engineering, which randomly combines genetic material into a host genome.

According to the National Center for Advancing Translational Sciences updates form June 2022, the Somatic Cell Genome Editing (SCGE) Program at the National Institutes of Health (NIH) has awarded 24 more grants to researchers across the United States and Canada.

Market Dynamics:

Driver:

Developments in genome editing

Recent developments have substantially improved genome editing capabilities, enabling the alteration of unique gene sequences in a variety of cell types and model species. In particular, for oncology tests, genome engineering has developed into a potentially game-changing diagnostic tool. Genome engineering was previously used by major research institutions, including those affiliated with the government and universities. This significant movement away from academics and into clinical and diagnostic facilities is primarily driven by the rapid advancement of gene editing technology.

Restraint:

High equipment costs

Because genomic instruments have cutting-edge features and functions, they are more expensive, with costs averaging between USD 10 and USD 20 million. As many of these systems are needed by pharmaceutical businesses and research labs, their capital expenditure to acquire several genomic equipment is very significant. It is not practical for small and medium-sized pharmaceutical corporations and research labs to invest substantially in numerous genomics devices.

Opportunity:

Extensive use of genome editing in personalized medicine

Players in the genome editing market should have opportunities as the field of customized medicine grows. With the aid of personalized medicine, practitioners may identify a patient's precise needs and then prescribe medications and treatments in response. Due to its potential for cost reductions, better patient compliance, early disease identification, and therapy improvement, the use of customized medicine is expanding globally.

Threat:

Off-target effects of CRISPR technology

CRISPR-Cas9's off-target consequences are a significant concern. Any off-target nuclease activity may modify these genes and result in oncogenesis since Cas9 generates double-stranded breaks. One to three mismatches in the target can be tolerated by CRISPR-Cas9, which can result in off-target nuclease activity. A significant concern is the high frequency of off-target activity (50%), which refers to alterations at locations other than the planned on-target site. For instance, CRISPR can activate the cancer-causing gene or target the tumor suppressor gene. Due to this undesirable effect, numerous companies that are organizing clinical studies have experienced problems. Clinical trials have been revoked, and regulatory authorities demand more studies to improve the safety of this procedure.

Covid-19 Impact:

COVID-19 has a favorable effect on the market for genome editing. The COVID-19 epidemic has increased the strain on healthcare systems around the world. Major pharmaceutical and biotechnology companies have increased their investments in vaccine R&D and market players for genome editing as a result of the COVID-19 pandemic. Due to the rising demand for vaccinations and potential antiviral medications, genome editing and engineering technologies are at the forefront of scientific research. Additionally, there has been a moderate impact on the market for genome editing as well as other healthcare services. Many researchers switched their attention to the investigation of this unique virus and the illness it produces after COVID-19 was originally identified.

The clustered regularly interspaced short palindromic repeats (CRISPR) segment is expected to be the largest during the forecast period

Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) segment is expected to have moderate growth over the projected period because of increased government financing and initiatives to develop vaccinations, medical technology, pharmaceuticals, and gadgets. In two cases of inherited diseases—one in a patient with TDT (thalassemia) and the other in a patient with SCD (sickle cell disease)—CRISPR-Cas9-based gene editing is being tested, according to a study titled CRISPR-Cas9 Gene Editing for Sickle Cell Disease and -Thalassemia, published in the New England Journal of Medicine in January 2021. Both patients witnessed early, significant, and long-lasting increases in fetal hemoglobin levels with more than 99% pancellularity throughout the course of the following year after receiving CTX001. Therefore, it is anticipated that over the forecast period, demand for CRISPR technology will increase due to its use in treating diseases including sickle cell disease and beta-thalassemia.

The cell line editing segment is expected to have the highest CAGR during the forecast period

Due to the expanding use of cell line engineering in stem cell-based research, it is predicted that the cell line editing segment will have profitable growth over an extended period. Cell line engineering is widely used for induced pluripotent stem cells (iPSCs), which help to change the genetic material of the cells as a result of rapid improvements. Additionally, advanced gene editing methods, including zinc finger nucleases (ZFNs), CRISPR/Cas, and TALENs, have made cell editing affordable and feasible.

Region with largest share:

Due to the biotechnology and pharmaceutical industries' strong development trends, North America has acquired a monopoly on the global market for genome editing. During the anticipated period, it is predicted that factors including technological advancements in genome editing, rising product approvals, and expanding R&D procedures would accelerate market expansion. However, the United States Food and Drug Administration provided consent to researchers at the University of California (UC), San Francisco, UC Berkeley, and UC Los Angeles in March 2021 to jointly begin an early-phase, first-in-human clinical trial of a gene correction therapy in sickle cell disease patients using the patient's blood-forming stem cells.

Region with highest CAGR:

Due to the advancement of gene therapy, growing consumption of genetically modified crops, and easy access to research funding, North America hold the highest CAGR over the forecasted period and will continue to make the largest contribution to businesses offering tools and services for gene editing. Additionally, the U.S. controls the majority of the market in North America, mostly as a result of increased public and private financing for genomics research. Furthermore, the market for genome editing in North America is being driven by the rising prevalence of rare illnesses in the United States and Canada. More than 7,000 rare diseases affect between 25 and 30 million Americans, according to the National Institutes of Health (NIH). According to this statistic, one in ten Americans has a rare disorder. As a result, the adoption of novel DNA editing methods in these nations is driven by the growing need to provide effective medications.

Key players in the market

Some of the key players in Genome Editing market include Agilent Technologies Inc., AstraZeneca, Beam Therapeutics, Bluebird Bio, Caribou Biosciences, Inc, Cellectis S.A., Cibus, Recombinetics, Inc., CRISPR Therapeutics AG, Editas Medicine Inc., Egenesis Inc., GenScript Biotech Corporation, GenScript USA Inc., Horizon Discovery Group plc, Integrated DNA Technologies Inc., Intellia Therapeutics, Inc., Lonza Group Ltd, Merck KGaA, New England Biolabs Inc., Origene Technologies Inc., Precision BioSciences Inc., Sangamo Therapeutics Inc., Takara Bio Inc., Tecan Life Sciences , Thermo Fisher Scientific Inc. and Transposagen Biopharmaceuticals Inc.

Key Developments:

In May 2022, the English parliament introduced a Bill that would enable the release of genetically edited products. The Genetic Technology (Precision Breeding) Bill aims to benefit companies, farmers, and consumers. The bill is currently under the report stage in the House of Commons.

In February 2022, Integrated DNA Technologies unveiled Alt-R HDR Donor Blocks, an improved solution for increasing homology-directed repair (HDR) rates. Alt-R HDR Donor Blocks are the latest addition to IDT’s complete portfolio of Alt-R CRISPR genome editing solutions.

In February 2022, Intellia Therapeutics, Inc. and Regeneron Pharmaceuticals, Inc. announced the positive interim data from an ongoing Phase I clinical study of their lead in vivo genome editing candidate, NTLA-2001 (Investigational Crispr Therapy For Transthyretin (Attr) Amyloidosis).

In January 2022, CRISPR Therapeutics AG announced a strategic partnership with Capsida Biotherapeutics Inc. to develop new gene therapies using the CRISPR/Cas9 technology for the treatment of various diseases. Under the agreement, CRISPR Therapeutics will provide its genome editing expertise, while Capsida will contribute its adeno-associated virus (AAV) delivery technology.

Product & Services Covered:
• Reagents & Consumables
• Services
• Software & Systems
• Cell Lines
• Other Product & Services

Technologies Covered:
• Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)
• Zinc Finger Nuclease (ZFN)
• Transcription Activator-Like Effector Nuclease (TALEN)
• Antisense
• Restriction Enzymes
• Other Technologies

Applications Covered:
• Cell Line Editing
• Genetic Engineering
• Drug Discovery & Development
• Diagnostic Applications
• Microorganisms Genetic Engineering
• Gene Therapy
• Other Applications

End Users Covered:
• Clinical Research Organizations
• Academics & Government Research Institutes
• Pharmaceutical & Biotechnology Companies
• Contract Research Organization
• Other End Users

Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements


1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Technology Analysis
3.7 Application Analysis
3.8 End User Analysis
3.9 Emerging Markets
3.10 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Genome Editing Market, By Product & Service
5.1 Introduction
5.2 Reagents & Consumables
5.3 Services
5.4 Software & Systems
5.5 Cell Lines
5.6 Other Product & Services
6 Global Genome Editing Market, By Technology
6.1 Introduction
6.2 Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)
6.3 Zinc Finger Nuclease (ZFN)
6.4 Transcription Activator-Like Effector Nuclease (TALEN)
6.5 Antisense
6.6 Restriction Enzymes
6.7 Other Technologies
7 Global Genome Editing Market, By Application
7.1 Introduction
7.2 Cell Line Editing
7.3 Genetic Engineering
7.3.1 Plant Genetic Engineering
7.3.2 Animal Genetic Engineering
7.4 Drug Discovery & Development
7.5 Diagnostic Applications
7.6 Microorganisms Genetic Engineering
7.7 Gene Therapy
7.8 Other Applications
8 Global Genome Editing Market, By End User
8.1 Introduction
8.2 Clinical Research Organizations
8.3 Academics & Government Research Institutes
8.4 Pharmaceutical & Biotechnology Companies
8.5 Contract Research Organization
8.6 Other End Users
9 Global Genome Editing Market, By Geography
9.1 Introduction
9.2 North America
9.2.1 US
9.2.2 Canada
9.2.3 Mexico
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 Italy
9.3.4 France
9.3.5 Spain
9.3.6 Rest of Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 New Zealand
9.4.6 South Korea
9.4.7 Rest of Asia Pacific
9.5 South America
9.5.1 Argentina
9.5.2 Brazil
9.5.3 Chile
9.5.4 Rest of South America
9.6 Middle East & Africa
9.6.1 Saudi Arabia
9.6.2 UAE
9.6.3 Qatar
9.6.4 South Africa
9.6.5 Rest of Middle East & Africa
10 Key Developments
10.1 Agreements, Partnerships, Collaborations and Joint Ventures
10.2 Acquisitions & Mergers
10.3 New Product Launch
10.4 Expansions
10.5 Other Key Strategies
11 Company Profiling
11.1 Agilent Technologies Inc.
11.2 AstraZeneca
11.3 Beam Therapeutics
11.4 Bluebird Bio
11.5 Caribou Biosciences, Inc
11.6 Cellectis S.A.
11.7 Cibus, Recombinetics, Inc.
11.8 CRISPR Therapeutics AG
11.9 Editas Medicine Inc.
>
11.10 Egenesis Inc.
11.11 GenScript Biotech Corporation
11.12 GenScript USA Inc.
11.13 Horizon Discovery Group plc
11.14 Integrated DNA Technologies Inc.
11.15 Intellia Therapeutics, Inc.
11.16 Lonza Group Ltd
11.17 Merck KGaA
11.18 New England Biolabs Inc.
11.19 Origene Technologies Inc.
11.20 Precision BioSciences Inc.
11.21 Sangamo Therapeutics Inc.
11.22 Takara Bio Inc.
11.23 Tecan Life Sciences
11.24 Thermo Fisher Scientific Inc.
11.25 Transposagen Biopharmaceuticals Inc.
List of Tables
>
Table 1 Global Genome Editing Market Outlook, By Region (2020-2028) ($MN)
>
Table 2 Global Genome Editing Market Outlook, By Product & Service (2020-2028) ($MN)
>
Table 3 Global Genome Editing Market Outlook, By Reagents & Consumables (2020-2028) ($MN)
>
Table 4 Global Genome Editing Market Outlook, By Services (2020-2028) ($MN)
>
Table 5 Global Genome Editing Market Outlook, By Software & Systems (2020-2028) ($MN)
>
Table 6 Global Genome Editing Market Outlook, By Cell Lines (2020-2028) ($MN)
>
Table 7 Global Genome Editing Market Outlook, By Other Product & Services (2020-2028) ($MN)
>
Table 8 Global Genome Editing Market Outlook, By Technology (2020-2028) ($MN)
>
Table 9 Global Genome Editing Market Outlook, By Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) (2020-2028) ($MN)
>
Table 10 Global Genome Editing Market Outlook, By Zinc Finger Nuclease (ZFN) (2020-2028) ($MN)
>
Table 11 Global Genome Editing Market Outlook, By Transcription Activator-Like Effector Nuclease (TALEN) (2020-2028) ($MN)
>
Table 12 Global Genome Editing Market Outlook, By Antisense (2020-2028) ($MN)
>
Table 13 Global Genome Editing Market Outlook, By Restriction Enzymes (2020-2028) ($MN)
>
Table 14 Global Genome Editing Market Outlook, By Other Technologies (2020-2028) ($MN)
>
Table 15 Global Genome Editing Market Outlook, By Application (2020-2028) ($MN)
>
Table 16 Global Genome Editing Market Outlook, By Cell Line Editing (2020-2028) ($MN)
>
Table 17 Global Genome Editing Market Outlook, By Genetic Engineering (2020-2028) ($MN)
>
Table 18 Global Genome Editing Market Outlook, By Plant Genetic Engineering (2020-2028) ($MN)
>
Table 19 Global Genome Editing Market Outlook, By Animal Genetic Engineering (2020-2028) ($MN)
>
Table 20 Global Genome Editing Market Outlook, By Drug Discovery & Development (2020-2028) ($MN)
>
Table 21 Global Genome Editing Market Outlook, By Diagnostic Applications (2020-2028) ($MN)
>
Table 22 Global Genome Editing Market Outlook, By Microorganisms Genetic Engineering (2020-2028) ($MN)
>
Table 23 Global Genome Editing Market Outlook, By Gene Therapy (2020-2028) ($MN)
>
Table 24 Global Genome Editing Market Outlook, By Other Applications (2020-2028) ($MN)
>
Table 25 Global Genome Editing Market Outlook, By End User (2020-2028) ($MN)
>
Table 26 Global Genome Editing Market Outlook, By Clinical Research Organizations (2020-2028) ($MN)
>
Table 27 Global Genome Editing Market Outlook, By Academics & Government Research Institutes (2020-2028) ($MN)
>
Table 28 Global Genome Editing Market Outlook, By Pharmaceutical & Biotechnology Companies (2020-2028) ($MN)
>
Table 29 Global Genome Editing Market Outlook, By Contract Research Organization (2020-2028) ($MN)
>
Table 30 Global Genome Editing Market Outlook, By Other End Users (2020-2028) ($MN)
>
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.
>

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings